PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cutaneous leishmaniasis.

Abstract There is no effective vaccine for the prevention and elimination of leishmaniasis. For this reason, we assessed the protective effects of DNA vaccines containing LeIF, TSA genes alone, or LeIF-TSA fusion against cutaneous leishmaniasis pEGFP-N1 plasmid (empty vector) and phosphate buffer saline (PBS) were used as control groups. Therefore, cellular and humoral immune responses were evaluated before and after the challenge with Leishmania major. Lesion diameter was also measured 3-12 weeks after challenge. All immunized mice with plasmid DNA encoding Leishmania antigens induced the partial immunity characterized by increased IFN-γ and IgG2a levels compared with control groups (p < 0.001). Furthermore, the immunized mice showed significant reduction in mean lesion sizes compared with mice in empty vector and PBS groups (p < 0.05). The reduction in lesion diameter was 29.3%, 34.1%, and 46.2% less in groups vaccinated with LeIF, TSA, and LeIF-TSA, respectively, than in PBS group at 12th week post infection. IFN/IL-4 and IgG2a/IgG1 ratios indicated that group receiving LeIF-TSA fusion had the highest IFN-γ and IgG2a levels. In this study, DNA immunization promoted Th1 immune response characterized by higher IFN-γ and IgG2a levels and also reduction in lesion size. These results showed that a bivalent vaccine containing two distinct antigens may induce more potent immune responses against leishmaniasis.
PMID
Related Publications

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Codelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice.

Authors

Mayor MeshTerms

Leishmaniasis, Cutaneous

Keywords

Leishmania major

Leishmania eukaryotic initiation factor

fusion

thiol-specific antioxidant

vaccine

Journal Title apmis : acta pathologica, microbiologica, et immunologica scandinavica
Publication Year Start




PMID- 28233451
OWN - NLM
STAT- MEDLINE
DA  - 20170224
DCOM- 20170310
LR  - 20170310
IS  - 1600-0463 (Electronic)
IS  - 0903-4641 (Linking)
VI  - 125
IP  - 3
DP  - 2017 Mar
TI  - Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA
      genes against murine cutaneous leishmaniasis.
PG  - 249-258
LID - 10.1111/apm.12651 [doi]
AB  - There is no effective vaccine for the prevention and elimination of
      leishmaniasis. For this reason, we assessed the protective effects of DNA
      vaccines containing LeIF, TSA genes alone, or LeIF-TSA fusion against cutaneous
      leishmaniasis pEGFP-N1 plasmid (empty vector) and phosphate buffer saline (PBS)
      were used as control groups. Therefore, cellular and humoral immune responses
      were evaluated before and after the challenge with Leishmania major. Lesion
      diameter was also measured 3-12 weeks after challenge. All immunized mice with
      plasmid DNA encoding Leishmania antigens induced the partial immunity
      characterized by increased IFN-gamma and IgG2a levels compared with control
      groups (p &lt; 0.001). Furthermore, the immunized mice showed significant reduction 
      in mean lesion sizes compared with mice in empty vector and PBS groups (p &lt;
      0.05). The reduction in lesion diameter was 29.3%, 34.1%, and 46.2% less in
      groups vaccinated with LeIF, TSA, and LeIF-TSA, respectively, than in PBS group
      at 12th week post infection. IFN/IL-4 and IgG2a/IgG1 ratios indicated that group 
      receiving LeIF-TSA fusion had the highest IFN-gamma and IgG2a levels. In this
      study, DNA immunization promoted Th1 immune response characterized by higher
      IFN-gamma and IgG2a levels and also reduction in lesion size. These results
      showed that a bivalent vaccine containing two distinct antigens may induce more
      potent immune responses against leishmaniasis.
CI  - (c) 2017 APMIS. Published by John Wiley &amp; Sons Ltd.
FAU - Maspi, Nahid
AU  - Maspi N
AD  - Department of Medical Parasitology, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Ghaffarifar, Fatemeh
AU  - Ghaffarifar F
AD  - Department of Medical Parasitology, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Sharifi, Zohreh
AU  - Sharifi Z
AD  - Blood Transfusion Research Center, High Institute for Research and Education in
      Transfusion Medicine, Tehran, Iran.
FAU - Dalimi, Abdolhossein
AU  - Dalimi A
AD  - Department of Medical Parasitology, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Dayer, Mohammad Saaid
AU  - Dayer MS
AD  - Department of Medical Parasitology, Faculty of Medical Sciences, Tarbiat Modares 
      University, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - APMIS
JT  - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
JID - 8803400
RN  - 0 (LeIF protein, Leishmania)
RN  - 0 (Peptide Initiation Factors)
RN  - 0 (Protozoan Proteins)
RN  - 0 (Vaccines, DNA)
RN  - EC 1.11.1.15 (Peroxiredoxins)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Disease Models, Animal
MH  - Female
MH  - *Leishmaniasis, Cutaneous
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Peptide Initiation Factors/*genetics/immunology
MH  - Peroxiredoxins/genetics/*immunology
MH  - Polymerase Chain Reaction
MH  - Protozoan Proteins/*genetics/immunology
MH  - Vaccines, DNA/genetics/*immunology
OTO - NOTNLM
OT  - Leishmania major
OT  - Leishmania eukaryotic initiation factor
OT  - fusion
OT  - thiol-specific antioxidant
OT  - vaccine
EDAT- 2017/02/25 06:00
MHDA- 2017/03/11 06:00
CRDT- 2017/02/25 06:00
PHST- 2015/09/19 [received]
PHST- 2016/11/15 [accepted]
AID - 10.1111/apm.12651 [doi]
PST - ppublish
SO  - APMIS. 2017 Mar;125(3):249-258. doi: 10.1111/apm.12651.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>